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Nucleotide sugars are the activated form of monosaccharides used by glycosyltransferases
during glycosylation. In eukaryotes the SLC35 family of solute carriers are responsible for
their selective uptake into the Endoplasmic Reticulum or Golgi apparatus. The structure of the
yeast GDP-mannose transporter, Vrg4, revealed a requirement for short chain lipids and a
marked difference in transport rate between the nucleotide sugar and nucleoside mono-
phosphate, suggesting a complex network of regulatory elements control transport into these
organelles. Here we report the crystal structure of the GMP bound complex of Vrg4,
revealing the molecular basis for GMP recognition and transport. Molecular dynamics,
combined with biochemical analysis, reveal a lipid mediated dimer interface and mechanism
for coordinating structural rearrangements during transport. Together these results provide
further insight into how SLC35 family transporters function within the secretory pathway and
sheds light onto the role that membrane lipids play in regulating transport across the
membrane.
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G lycosylation plays a crucial role in cell physiology,impacting numerous process from quality control duringprotein folding and subsequent protein trafﬁcking, to
cell recognition, developmental signalling and immune system
function1,2. Changes in cell surface glycosylation can modulate
inﬂammatory responses, promote cancer cell metastasis and
regulate apoptosis. Understanding the pathways that control
glycosylation in eukaryotic cells is therefore at the forefront of the
emerging ﬁeld of glycomedicine, which promises new therapeutic
routes to many human diseases3.
In eukaryotes, glycosylation occurs in the lumen of either the
Endoplasmic Reticulum (ER) or Golgi Apparatus (Golgi), where
speciﬁc glycosyltransferase enzymes recognise donor sites on
either proteins or lipids to build up a complex array of carbo-
hydrate structures4. However, to function efﬁciently, glycosyl-
transferases require a continuous supply of activated nucleotide
sugars, which act as the precursors to the glycan structures that
are built on protein and lipid molecules. Nucleotide sugars
contain a single carbohydrate attached via a phosphodiester
bond to either a nucleoside diphosphate or nucleoside mono-
phosphate carrier group5. The labile nature of the phosphate
bond plays an important role in the enzymatic mechanism that
transfers the sugar group during glycosylation. Mammals use
nine nucleotide sugars for glycosylation5, with CMP-Sialic acid
and GDP-fucose being the only ones to utilise cytosine and
guanine nucleotides, whilst the remaining seven sugars are all
conjugated to uridine.
Nucleotide sugars are synthesised in either the cytoplasm or
nucleus and must be transported across the ER and Golgi
membranes through the action of nucleotide sugar transporters
(NSTs)6. Following their use by the glycosyltransferases the
resulting nucleoside diphosphate is then processed by a luminal
phosphatase, before being transported back across the membrane
as a nucleoside monophosphate (NMP) through the same
transport proteins7. NSTs thus play an important role in reg-
ulating glycosylation by controlling the transport of essential
activated sugars to the glycosyltransferase enzymes and trans-
porting the NMPs back into the cytosol to be regenerated.
NSTs belong to the SLC35 family of solute carriers and are
highly conserved from simple eukaryotes like fungi and parasites
to complex multicellular organisms such as plants and mam-
mals8. NSTs are divided into seven subfamilies, designated A-G
based on the speciﬁc nucleotide sugar they transport9. The ﬁrst
crystal structure for a member of the SLC35 family, the GDP-
mannose transporter from Saccharomyces cerevisiae Vrg4, was
recently reported in its substrate free and nucleotide sugar bound
states10. This was recently followed by structures of both the
mouse and maize CMP-sialic acid transporters11,12. These
structures reveal a conserved architecture for the SLC35 family
consisting of 10 transmembrane helices arranged around a central
ligand binding site in a ﬁve plus ﬁve conﬁguration13.
The transport of GDP-mannose is important for pathogenic
fungi, such as Candida albicans, Aspergillus fumigatus and
Cryptococcus neoformans14,15. These organisms contain a cell wall
predominantly formed of glycomannosylated conjugates that
form a protective coat against the human immune system. GDP-
mannose transport is fundamental for virulence and essential for
cell survival, making the transporters attractive targets for inhi-
bitor design16. The recent crystal structure of Vrg4 bound to
GDP-mannose (PDB: 5OGE) now provides opportunities for
structure-based drug design targeted at this class of transporter.
The structure revealed speciﬁcity pockets that separate recogni-
tion of the nucleotide and sugar groups, revealing sequence
motifs that appear to correlate with substrate speciﬁcity. Never-
theless, structural information concerning the recognition of
GMP still remains unknown, hampering efforts to fully under-
stand ligand recognition. It was also observed that transport rates
between GDP-mannose and the anti-ported ligand, guanine
monophosphate (GMP), were different; with GDP-mannose
being transported at a faster rate compared to GMP10. This dif-
ference in transport rate may explain how NSTs achieve direc-
tional transport across the ER and Golgi membranes. The
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Fig. 1 Crystal structure of Vrg4 bound to GMP. a Crystal structure of Vrg4 with helices coloured blue (N-terminus) to red (C-terminus). The binding cavity
is open to the Golgi lumen, and shown as a transparent surface (wheat). The three different positions observed for the GMP molecule are overlaid in blue,
orange and pink. The position of the lipid bilayer is indicated by white dashed lines. b An overlay showing the three GMP molecules as presented in a, with
arrows highlighting the changes in positions observed for the nucleoside and phosphate groups. c, d, e Zoomed in views of the binding site from chains C, D
and E respectively, showing the different positions and interactions made to GMP in the crystal structure
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discovery that Vrg4 requires short chain lipids to function also
suggested a second route by which nucleotide sugar transport
could be regulated in the cell. Given the highly dynamic mem-
brane environment of the ER and Golgi, the concept that trans-
port proteins can be regulated using speciﬁc lipids and bulk
bilayer properties, such as local structure and membrane thick-
ness, is an exciting, but poorly understood area of membrane
biology.
To address these questions we sought to determine the struc-
ture of Vrg4 bound to the nucleoside monophosphate, GMP and
analyse how lipids regulate the oligomeric state and function of
the transporter. Our structure reveals that GMP is accommodated
in different orientations within the binding site, explaining why
counter transport of this ligand is less efﬁcient than with GDP-
mannose. Using a combination of coarse grained and all atom
molecular dynamics, our study also demonstrates how short
chain lipids likely regulate transporter function and facilitate
dimer formation in the membrane.
Results
GMP adopts different conformations in the binding site. The
difference observed between the transport of GDP-mannose and
GMP raised the question of whether the nucleoside monopho-
sphate was recognised in a different way within the binding site.
To understand how GMP is recognised by Vrg4 we determined a
co-crystal structure with GMP at 3.3 Å resolution (Fig. 1a and
Supplementary Table 1). Vrg4 adopts a very similar pose as that
for the GDP-mannose transporter (root mean square deviation
~0.47 Å between 276 Cα atoms), with the binding site open to the
luminal side of the Golgi membrane and sealed shut on the
cytoplasmic side through the packing together of TM6 & TM7
against TM8 and TM9. Clear mFo-DFc difference electron density
was observed for the GMP ligand in three of the eight trans-
porters in the unit cell (Supplementary Fig. 1). Unexpectedly the
three GMP ligands adopt slightly different positions within the
three binding sites (Fig. 1b), despite a r.m.s.d of only 0.45 Å
between the three structures. In two of the three positions the
GMP ligand adopts an extended conformation (Fig. 1c, d).
However, in the third position captured, the GMP adopts a bent
conﬁguration, with the phosphate group pointing down towards
the Golgi lumen (Fig. 1e). In chain C, the phosphate group of the
GMP molecule forms a salt bridge with a conserved lysine (K289)
on TM9 and interacts with a conserved tyrosine on TM1 (Y28)
through a hydrogen bond (Fig. 1c). Lysine 289 forms part of the
previously identiﬁed GALNK289 motif, which plays an important
role in discriminating between sugar groups of different nucleo-
tide sugar molecules10. The interaction with Y28 is consistent
with the essential role this side chain has in transport10. Moving
along the GMP molecule, the ribose group also interacts with
TM9 via another conserved tyrosine (Y281), which, although not
strictly conserved, must be a bulky side chain to support trans-
port10. Interestingly, the orientation of the ribose ring is sig-
niﬁcantly different to that observed in the GDP-mannose
structure, resulting in an interaction between Y281 and the ring
oxygen instead of the two hydroxyl oxygens (Supplementary
Fig. 2). At the far end of the ligand the guanine ring is ﬂipped
180° relative to that of GDP-mannose, but still sits within the
previously observed nucleotide binding pocket. This pocket is
characterised by the presence of a conserved FYNN221 motif on
TM7, which is required for guanine recognition. Similar con-
served motifs are observed in other families of nucleotide sugar
transporters in this region of the binding site, consistent with a
general importance of TM7 in nucleotide recognition11,13.
However, unlike the GDP-mannose ligand, GMP does not make a
direct interaction to the conserved asparagines of the FYNN
motif, which are ~4.5 Å away. Instead the guanine interacts with a
conserved serine (S266) on TM8, via an interaction with the ring
nitrogen.
In chain D the GMP ligand adopts a similar extended position
to that observed in chain C, with the guanine ring again ﬂipped
180° relative to that observed in the GDP-mannose structure
(Fig. 1d and Supplementary Fig. 2). Overall the interactions
between the GMP in chain D and those in chain C are similar
despite the different orientation of the ribose ring (Fig. 1b). S266
interacts with the ring nitrogen on the guanine base, Y281 with
the ribose ring oxygen, while K289 interacts with the phosphate
group. However, a surprising ﬁnding from our analysis of the
GMP co-crystal structures was the unusual position of the GMP
ligand in chain E (Fig. 1b). Unlike the position of the GMP ligand
in chains C and D, the molecule adopts a bent conﬁguration, with
the phosphate group now orientated towards the luminal
entrance of the binding site (Fig. 1e). In this position the
phosphate now interacts with a conserved serine on TM1 (S32),
rather than K289, which adopts a different rotamer conﬁguration
compared to chains C and D (Supplementary Fig. 3). The ribose
group sits in a similar location within the binding site to that
observed in chains C and D, but now Y281 interacts with the O2
hydroxyl rather than the ring oxygen, similar to that observed
previously with GDP-mannose (Supplementary Fig. 2). In this
position the guanine ring now sits further into the nucleotide
binding pocket compared with the carbonyl group positioned
near to asparagine N221 of the FYNN221 motif. An additional
interaction is also observed between the ring nitrogen of the
nucleotide (N3) and a conserved serine on TM8 (S269), which
was previously observed interacting with the ribose hydroxyl
oxygen in the GDP-mannose structure. Taken together, the
different positions of GMP within the crystal structure suggested
that Vrg4 recognises GMP differently to GDP-mannose, which as
we discuss below, is important for understanding how these
transporters discriminate between nucleoside monophosphate
and nucleotide sugar in the cell.
Speciﬁc residues discriminate between ligands. Although GMP
adopts three different positions within the binding site, it is
notable that in all three poses an interaction with Y281 on TM9 is
observed. Previously we showed that a conservative mutation to
phenylalanine retained activity whereas an alanine variant was
non-functional10. However, given the prominent role that Y281
plays in GMP recognition we performed a more in-depth IC50
analysis on the Y281F variant (Fig. 2a). We observed that the
afﬁnity of this variant for GDP-mannose remains the same as
wild type (WT; 7.6 μM10), however the IC50 for GMP increased to
23 μM, indicating a hydroxyl at this position aids recognition of
the GMP ligand. Given that Y281 appears to discriminate
between the two ligands, we sought to identify additional side
chains that are important for GMP transport. Tyrosine 28 is
essential, and its replacement with alanine abolishes transport,
and K289 is important for sugar recognition and transport10.
However, our structures also identiﬁed serines 266 and 269 as
interacting with the guanine base. Interestingly, we observed a
similar result to that of Y281 with S266, with an alanine variant
resulting in a signiﬁcant increase in the IC50 value for GMP
transport, whilst the afﬁnity for GDP-mannose was only slightly
reduced (Fig. 2b). The similar afﬁnity for GDP-mannose as WT
in this mutant is most likely due to the additional interactions
formed between the GALNK motif and the mannose moiety
compensating for the loss of interaction sites on the guanine base.
Removal of S269 on the other hand did not result in any sig-
niﬁcant change in the IC50 for either GMP or GDP-mannose
(Fig. 2c). Our analysis of the binding site shows that Vrg4 is able
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to discriminate between GMP and GDP-mannose ligands and
that different sets of residues are important for transport of either
ligand.
Structural explanation for transport rate differences. NSTs are
obligate antiporters, requiring the movement of one ligand in
exchange for another. In the cell NSTs function to shuttle
nucleotide sugars into the lumen of the ER or Golgi, in exchange
for the cognate nucleoside monophosphate7. An important
question has been how these systems ensure the direction of
transport for their ligands. Previously we showed that Vrg4
functions at different rates depending on the ligands it is moving
across the membrane, with GDP-mannose:GMP being more
efﬁcient than GMP:GMP in liposome-based assays10. The GMP
co-crystal structures now provides an explanation for this phe-
nomenon. It appears that GMP is simply less efﬁcient at docking
into the binding site and triggering transport compared to the
larger GDP-mannose, which interacts with more sites in the
protein. However, if this structural hypothesis is correct and the
observed rate difference is caused by a more ﬂexible binding
position, we would predict that GDP-mannose:GDP-mannose
antiport via Vrg4 would have a faster transport rate due to the
lack of alternative interaction positions available with this larger
ligand. Similarly, a ligand that makes fewer interactions than
GMP, such as AMP (discussed below), would be expected to have
a slower rate. We tested this hypothesis using a liposome-based
assay and monitoring transport of both radiolabelled GMP and
GDP-mannose. We observed the fastest transport rate when
GDP-mannose is transported against itself and the slowest for
GMP:AMP antiport (Fig. 2d and Supplementary Fig. 4),
conﬁrming that the transport rate of Vrg4 correlates with the
number of interactions made between the transporter and
substrate.
Structural basis of nucleotide speciﬁcity. The features that
underpin substrate selectivity in the SLC35 family are unclear,
with sequence identity being a poor predictor of ligand recogni-
tion9. However, previously identiﬁed putative sequence motifs in
Vrg4 appear to correlate with substrate speciﬁcity, which may
facilitate sequence based functional assignment within the SLC35
family11,13. Speciﬁcally, in Vrg4 the FYNN221 motif located on
TM7 was linked to recognition of the guanine base. Vrg4 shows
strict substrate speciﬁcity with respect to the nucleotide moiety,
being able to recognise only purine bases (Supplementary Fig. 5).
Within the purine bases, the native substrate GMP is transported
with a much higher afﬁnity (IC50 7 μM) compared to AMP (IC50
50 μM). It is known that the asparagines in the FYNN221 motif
are important for ligand recognition, but it is unclear what role
they play10. To further understand this role, we analysed their
ability to discriminate between the different purine bases. Alanine
variants of both N220 and N221 resulted in a higher IC50 for
GMP than the WT protein; N220A 12 μM and N221A 22 μM
(Fig. 3a). This result suggests that both asparagines are used to
recognise and position the amino and carbonyl groups on the
GMP ligand, and explains why AMP, with only one amino group
is recognised at a much lower afﬁnity than the WT protein.
Analysis of the IC50 of the mutants for AMP however, shows that
for the N220A variant the afﬁnity for AMP is markedly reduced,
suggesting that the remaining asparagine, N221 cannot interact as
well with the amine of AMP as it can with the carbonyl of GMP.
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However, the N221A variant has IC50 values for AMP and GMP
which are very similar to each other, 27 μM and 22 μM respec-
tively, thereby no longer discriminating between these nucleotides
(Fig. 3b). This result thus demonstrates that within the FYNN221
motif, N221 plays a more signiﬁcant role in purine selectivity.
These biochemical data are supported by the structural compar-
ison between the GMP and the GDP-mannose structures (Sup-
plementary Fig. 2), which show that a similar feature observed in
all conformations captured is the position of the carbonyl group
close to N221.
Lipids play an important role in mediating dimerisation. NSTs
involved in the transport of UDP-GalNac, GDP-fucose, PAPS (3′
phosphoadenosine-5′-phosphosulphate) and GDP-mannose are
reported to form homo-oligomers ranging from dimers to hex-
amers17–19. However, the signiﬁcance of oligomerisation and the
role of lipids in regulating oligomeric state within the NST family
remain unknown. Analysis of the apo, GMP and GDP-mannose
bound structures of Vrg4 show the presence of well−ordered
monoolein lipid molecules at a potential dimer interface. The
dimer interface is formed between TM5 and 10 and contains two
well-ordered monoolein lipid molecules, which contribute ~60%
to the total buried surface area of 1514 Å2 (Fig. 4a)20. Although
Vrg4 crystallises as a dimer in monoolein, in detergent the pro-
tein is monomeric10, raising the question of whether lipids induce
dimer formation in Vrg4 and what implication dimerisation may
have for function. To test the impact of the lipid environment on
stabilisation of the protein we used a thermal shift assay, which
has been used to test membrane protein lipid interactions21. We
noticed that in a lipid environment Vrg4 has a signiﬁcantly
higher melting temperature (~55 °C) than with either the deter-
gents decylmaltoside (DM) (33 °C) or dodecylmaltoside (DDM)
(38 °C) (Supplementary Fig. 6a). This large increase in melting
temperature in the presence of lipid could be indicative of further
stabilisation due to oligomerisation. We also observe possible
dimer formation in SDS PAGE analysis of Vrg4 reconstituted into
liposomes, which is not seen when the protein is in detergent,
even at high concentrations of protein (Fig. 4b and Supplemen-
tary Fig. 6b). This raised the question of whether Vrg4 is a
functional dimer in the membrane. To investigate whether
lipids can induce higher order oligomer formation we performed
glutaraldehyde crosslinking using protein puriﬁed under lipid
rich conditions. A dimer band can be observed in SDS–PAGE
which increases in intensity in the presence of both crosslinking
agent and additional yeast polar lipids, indicating that Vrg4 can
form higher order oligomers in the presence of lipid (Supple-
mentary Fig. 6c).
To further understand the role of lipids within the dimer
interface of Vrg4 we used molecular dynamics to embed Vrg4 in a
membrane composed of 1,2-dipalmitoyl-sn-glycero-3-phospho-
choline (DPPC) and 1,2-dimyristoyl-sn-glycero-3-phosphocho-
line (DMPC). These simulations conﬁrm that phospholipids
accumulate within the dimer interface observed in the crystal
structure (Fig. 4c, d). Interestingly, the MD simulations show that
the dimer interface can accommodate four DPPC lipids, arranged
as a bilayer (Supplementary Fig. 6d). This indicates that in the
native membrane environment the Vrg4 dimer will be held
together through stronger interactions, than in a detergent
micelle, consistent with our cross-linking analysis.
To test the functional signiﬁcance of dimerisation we
developed a dominant negative biochemical assay (Fig. 4e and
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Supplementary Fig. 6e). We reasoned that if equimolar amounts
of functional and non-functional Vrg4 were reconstituted into
liposomes, then random mixed dimers would form, containing
both active and inactivate transporters. If Vrg4 is a functional
dimer we would expect to see a greater than 50% reduction in
transport. However, we observed that mixing fully functional WT
protein with an inactive mutant, Y281A, discussed above, resulted
in exactly 50% transport activity. This result implies that each
monomer of Vrg4 acts as an independent functional unit, similar
to other dimers of SLC transporters22,23. We then repeated this
experiment, but instead used a K118A variant, which is transport
inactive but binding competent (Supplementary Fig. 6f), and
observed ~75% activity (Fig. 4e). Reconstituting at different ratios
(75 and 25% WT) also gave a higher than expected transport rate,
conﬁrming that Vrg4 forms oligomers within the liposome
membrane (Fig. 4e). Our interpretation of this data is that when
Vrg4 is in a mixed dimer, where one subunit is unable to
transport and in a locked conformation, the WT subunit is able to
cycle faster. This effect is most likely due to the increased stability
being imparted by an immobile partner, which provides a stable
platform against which the active transporter can move. This
phenomenon was also recently shown for the SLC26 anion
transporters, which despite being a different family also form
structural oligomers in the membrane24. In this study a similar
effect was observed, where the mixing of active and inactive
monomers created dimers with great than 50% activity. Together
with the structural, cross linking and MD data, we propose that
Vrg4 dimerises through an interface mediated by lipid molecules,
which form an integral part of the dimer.
Structural basis for short chain lipid dependence. The Golgi
membrane is known to have a different lipid composition in
comparison to the plasma membrane, which gives rise to a
thinner bilayer thickness25. Vrg4 transport activity is dependent
on short chain lipids to function, with a severe drop in activity
observed in longer chain lipids, such as 1-palmitoyl-2-oleoyl (PO)
lipids, which consist of one 16 and one 18 carbon fatty acid
chain10. However, the structural basis for this observation
remains obscure. This phenomenon could be due to hydrophobic
matching, especially given the short length of the hydrophobic
region of Vrg4. Indeed, when Vrg4 is inserted into a coarse
grained DPPC membrane, it results in the thinning of the bilayer
to more resemble the thickness of a DMPC bilayer (Supple-
mentary Fig. 7). Our simulation data from the mixed DMPC/
DPPC bilayers also showed the accumulation of lipid at an
additional site on the transporter (Fig. 5a, b). This second lipid
binding site only accommodates DMPC and not DPPC, and
occurs in a shallow groove between TMs 1, 9, and 10 (Fig. 5c and
Supplementary Fig. 8). The preference for DMPC over DPPC at
this site suggests lipids of 16 carbon chain lengths and above are
excluded, whereas the shorter DMPC lipid, with only a 14 carbon
acyl chain, can be accommodated. Based on a repeat swapped
model of the cytoplasmic facing state of Vrg4, we previously
suggested that TM9 is likely to play an important role in the
alternating access mechanism10. TM9 was also identiﬁed as being
important for the transition between luminal and cytoplasmic
facing conformations of the plant triose phosphate antiporter,
TpT, a distant homologue of the NST family26,27. These results
suggest that short chain lipids may allow TM9 to undergo the
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conformational changes necessary to cycle between inward and
outward facing states during transport.
Discussion
Nucleotide sugar transporters function as obligate exchangers,
swapping the activated sugar molecule in the cytoplasm for the
spent nucleoside monophosphate in the ER and Golgi lumen.
NSTs consist of 10 TM helices that are arranged as two inverted
topology repeats of ﬁve TMs, such that TM1-5 can be super-
imposed on TM6-10 via a 180° rotation in the plane of the
membrane10. Previously we identiﬁed that transport within the
NSTs occurs through the switching conformation of the ﬁrst four
helices that form each of the ﬁve TM bundles. Two pairs of
helices on either side of the binding site function as mobile gates,
which rock around the central binding site, dictating whether the
binding site is accessible to either the cytoplasm (inward facing)
and ER/Golgi lumen (outward facing). A long-standing question
in the NST ﬁeld has been whether a mechanism exists whereby
NSTs facilitate the direction of transport, such that adequate
supplies of nucleotide sugars are available to the glycosyl-
transferases. The recent discovery that Vrg4 indeed does
exhibit different rates of transport, such that GDP-mannose is
transported across the membrane with a faster rate than GMP,
demonstrates the internal mechanics of transport could play a
supporting role to the established concentration gradients across
these membranes. Several lines of evidence, including crystal
structures and steered MD of a related plant triosephosphate-
phosphate antiporter, TpT, along with our own analysis of a
cytoplasmic facing model of Vrg410, suggest that conserved side
chains on the main gating helices are likely to facilitate reor-
ientation of the transporter from inward to outward facing states
and vice versa following interactions with the bound ligands13,26.
Our ﬁndings that GMP adopts several similar, yet discrete con-
formations in the binding site now provides evidence that the
slower rate of transport observed for GMP vs. GDP-mannose is
due to less effective coupling between the ligand and the trans-
porter. The complex with GMP shows the guanine ring interacts
far less with the conserved FYNN221 motif of TM7, which is
responsible for distinguishing between adenine and guanine
(Fig. 3). In addition, the ribose group also appears to adopt
several conformations in the GMP structures, with only one
forming a strong interaction with Y281 on TM9, which is
essential for transport and one of the key gating helices13.
Interestingly, we noticed that K289 also on TM9, adopts a
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Fig. 5 Identiﬁcation of short chain lipid binding site. a Density plot of DMPC lipids around the Vrg4 dimer. In addition to the primary lipid binding sites on
the dimer interface (labelled 1), secondary binding sites can be observed (labelled 2) (green densities). b Views of Vrg4, with the densities from 4c and 5a
shown as coloured mesh. The protein is shown as surface, with each Vrg4 monomer coloured as white or grey. The primary binding site – marked ‘1’ in the
top left view – is occupied by both DMPC and DPPC. A secondary site – marked ’2’ – is exclusively occupied by DMPC. c View of the bound DMPC lipid in
the secondary binding site, following 30 ns of atomistic simulation. Residues interacting with the lipid are indicated as sticks and labelled and helices are
labelled
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substantially different rotamer conﬁguration between the GMP
and GDP-mannose structures (Supplementary Figs. 2 and 3). In
the GDP-mannose structure K289 makes an interaction with S32
on TM1 and the beta phosphate, functioning to connect these two
gating helices with GDP-mannose recognition. However, in the
GMP structure we observe K289 extending away from TM1, and
out towards the alpha phosphate group of GMP. Only two of the
three GMP molecules interact with K289, with the third GMP
adopting a bent conﬁguration that orientates the alpha phosphate
towards the luminal gate (Fig. 1e). The inability of GMP to
engage with K289 efﬁciently may explain why transport occurs at
a reduced rate. Given the important role that TM9 plays in
transport, it was intriguing to discover a lipid binding site con-
necting this helix to TM1. This would provide a further structural
link between the pairs of gating helices within the transporter,
providing an explanation for the short chain lipid dependence.
Taken together, these insights suggest a model for transport
within the NSTs, with an important role for the ligand in facil-
itating the rates of transport across the ER and Golgi membranes
(Fig. 6). The larger GDP-mannose ligand is able to dock more
efﬁciently in the binding site, resulting in faster transport, whilst
the smaller GMP is more mobile, requiring additional time to
efﬁciently interact with the pivot point residues and initiate
transport.
Finally, lipids are emerging as important regulators of sec-
ondary active transporters28,29. Our recent discovery that short
chain lipids have a role in regulating Vrg4 activity demonstrates a
speciﬁc role of lipids in this family of transporters and within the
dynamic membranes of the secretory pathway in eukaryotes.
Following the insertion of Vrg4 into lipid bilayers we observed
the presence of four well-ordered lipid molecules at the dimer
interface of Vrg4 (Fig. 4d). Within the SLC35 family, oligomer-
isation has been reported for several members, and evidence from
cell biology studies show that heterooligomers can be formed
between different NST monomers and N-acetylglucosaminyl-
transferases, potentially as a route to regulation17,19,30.
Interestingly, in Vrg4 we observe a dynamic oligomerisation
interface, where lipids appear to control dimer formation. This
opens up the exciting prospect that changing lipid environments
within the secretory pathway may function to regulate NST oli-
gomerisation and activity, inserting an additional level of control
on cellular glycosylation within the cell.
Methods
Protein expression and puriﬁcation. The gene encoding ScVrg4 (Uniprot
P40107) was ampliﬁed from Saccharomyces cerevisiae genomic DNA and cloned
into the pDDGFP-Leu2D vector (addgene 102334). Standard site directed muta-
genesis techniques were used to make variant forms of Vrg4. Wild type and variant
proteins were produced in S. cerevisiae strain BJ5460 (ATCC 208285) and puriﬁed
using standard nickel afﬁnity chromatography. Membranes were thawed and
solubilised in puriﬁcation buffer which consisted of, 1 × PBS containing an addi-
tional 150 mM NaCl and 10% glycerol and 1% n-dodecyl−β-D-maltopyranoside
(DDM, Glycon) with stirring for 1.5 h. The solubilised material was recovered
through ultracentrifugation at > 200,000 × g for 1 h. A ﬁnal concentration of 18
mM imidazole was added and the protein was bound to nickel resin (GE
Healthcare) in batch for 4 h. The resin was washed with puriﬁcation buffer con-
taining ﬁrst 18 mM imidazole and then 25 mM imidazole and 0.2% DDM for 15
and 25 column volumes respectively. Vrg4 was eluted from the resin with pur-
iﬁcation buffer containing 250 mM imidazole. TEV protease was added and the
protein was dialysed overnight in gel ﬁltration buffer containing 0.03 % DDM (20
mM Tris pH 7.5, 150 mM NaCl). After dialysis, the protein was passed through a
HisTrap column to remove the TEV protease and the GFP tag. The pure protein
was concentrated using a vivaspin 50,000 MWCO spin concentrator. Protein for
crystallisation was applied to a Superdex 200 10/300 gel ﬁltration column equili-
brated in a buffer consisting of 20 mM Tris–HCl pH 7.5 and 150 mM NaCl with
0.03% DDM, for reconstitution the detergent was changed to 0.3% n-decyl-β-D-
maltopyranoside.
Protein puriﬁcation and glutaraldehyde crosslinking. For the cross-linking
experiments Vrg4 was puriﬁed from membranes in puriﬁcation buffer, consisting
of 1 × PBS, 150 mM NaCl, 10% glycerol and 1% n-dodecyl−β-D-maltopyranoside
(DDM, Glycon) whilst stirring for 1.5 h at 4 °C. The solubilised material was
recovered through ultracentrifugation at > 200,000 × g for 1 h. A ﬁnal concentra-
tion of 18 mM imidazole was added and the protein was bound to nickel resin (GE
Healthcare) in batch for 4 h. The resin was washed with puriﬁcation buffer con-
taining 18 mM imidazole and followed by a second wash with 25 mM imidazole
containing 0.1% DDM for 8 and 10 column volumes respectively. Vrg4 was eluted
from the resin with puriﬁcation buffer containing 250 mM imidazole. TEV pro-
tease was added and the protein dialysed overnight in gel ﬁltration buffer con-
taining 0.015% DDM (20 mM Tris pH 7.5, 150 mM NaCl). After dialysis, the
protein was passed through a HisTrap column to remove the TEV protease and the
GFP tag. The pure protein was concentrated using a vivaspin 50,000 MWCO spin
concentrator to 0.5 ml and applied to a Superdex 200 10/300 gel ﬁltration column
equilibrated in a buffer consisting of PBS with 0.15 % DM.
For crosslinking 6 μg of protein were incubated in PBS with either 10 or 20 μg
yeast polar lipids (also in PBS and extruded through a 0.4 μm ﬁlter) for 30 min at
20 °C in a 10 μl volume. A ﬁnal concentration of 0.2% glutaraldehyde was added
and the reaction left for a further 20 min prior to the addition of 1 μl 1 M tris to
quench the reaction. Samples were loaded onto a 12% SDS–PAGE gel and stained
with Coomassie blue.
Crystallisation. Crystallisation was performed using protein at 40 mgml−1 ﬁnal
concentration, as determined using absorbance at 280 nm. In total 10 mM GMP
was incubated with the protein on ice for at least 2 h prior to LCP set up. Protein-
laden mesophase was obtained by mixing monoolein with protein in a 60:40 (w/w)
ratio using a coupled syringe device (Art Robbins, USA). Crystals appeared at 4 °C
in an optimised crystallisation screen consisting of 26–30% (v/v) PEG 400, 0.1 M
sodium citrate pH 5.0 and 75 mM sodium chloride or sodium acetate. Crystals
grew and within 4 days after initial set up the top glass plate was removed with a
glass scribe and 2 μl of crystallisation solution containing 20 mM GMP was added.
The well was resealed using a thin glass coverslip and left for at least 18 h. Crystals
were harvested using 30 µm micromounts before ﬂash cooling in liquid nitrogen.
Structure determination. X-ray diffraction data were collected at beamline
Proxima 2a at Soleil, France to 3.39 Å resolution. Indexing and integration were
performed with XDS31, followed by scaling and merging with AIMLESS32. Initial
phases were obtained by molecular replacement (MR) using PHASER33 in the
CCP4 suite34. The search model was the previously determined crystal structure of
Vrg4 (PDB: 5OGE). Model building into the electron density map was performed
with COOT35, with structure reﬁnement carried out in PHENIX36. Model vali-
dation was carried out using Molprobity37. Images were prepared using PyMol.
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Fig. 6 Model of alternating access mechanism in Vrg4. a Vrg4 adopts an
inward open state with the binding site orientated towards the cytosol.
GDP-mannose binds, resulting in the fast interconversion to the outward
open state b, facing the Golgi lumen. c Following release of the GDP-
mannose, GMP binds the transporter. The smaller size of GMP results in
less efﬁcient transport, resulting in a slower interconversion back to the
inward open state d The key gating helices are TM1, 2 and 3, 4 that
alternate around the central binding site. e Short chain lipids are necessary
to facilitate the movement of the gating helices, with the transporter being
inactive in longer chain lipids
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Protein reconstitution into liposomes. Vrg4 was reconstituted into liposomes
made from yeast polar lipids using the dilution method into preformed lipid
vesicles38. Chloroform was removed from yeast polar lipids (Avanti polar lipids)
through the use of a rotary evaporator to obtain a thin ﬁlm. The lipids were washed
twice in pentane and then resuspended at 5 mgml−1 in lipid buffer (20 mM
HEPES pH 7.5, 100 mM KCl). These lipid vesicles were frozen and thawed twice in
liquid nitrogen and stored at −80 °C until required. For reconstitution, the lipids
were thawed and then extruded ﬁrst through a 0.8-μm ﬁlter and then through a
0.4-μm ﬁlter. Puriﬁed Vrg4 in DM (at 0.5 μg μl−1 concentration) was added to the
lipids at a ﬁnal lipid:protein ratio of 80:1 and incubated for 1 h at room tem-
perature, then for a further 1 h on ice; for the no-protein liposome control, the
same volume of gel ﬁltration buffer containing 0.3% DM was added. After this
time, the protein–lipid mix was diluted rapidly into 65 ml of assay buffer (20 mM
HEPES pH 7.5, 50 mM KCl, 2 mM MgSO4) and proteoliposomes were collected
through centrifugation at > 200,000 × g for 2 h. To remove trace detergent the
proteoliposomes were dialysed overnight against a large volume of assay buffer.
After dialysis, the proteoliposomes were collected and resuspended in assay buffer
to a ﬁnal protein concentration of 0.25 μg μl−1, and then subjected to three rounds
of freeze–thawing in liquid nitrogen before storage at −80 °C. The amount of
protein (both wild-type and mutant variants) reconstituted into the lipids was
quantiﬁed by SDS–PAGE and densitometry.
For the dominant negative assays the required ratios of wild type and mutant
variants were mixed in detergent, left for one hour on ice prior to reconstitution as
above. In order to validate the data from these experiments the reconstitution of
the different ratios were repeated in duplicate from separate puriﬁcations of both
wild type and mutant proteins.
Transport assays. To analyse transport activity, proteoliposomes were thawed and
the desired concentration of internal substrate was added (typically 0.5 mM for
mutant variant analysis). To load the liposomes, they were subjected to six rounds
of freeze–thaw in liquid nitrogen and then extruded through a 0.4-μm membrane.
The equivalent of 1 μg of protein was added to 50 μl of assay buffer containing 0.5
μM 3H-GMP, which initiated the transport. All assays were performed at 30 °C
unless stated otherwise. The uptake of radiolabelled substrate was stopped at the
desired time by rapidly ﬁltering onto 0.22-μm ﬁlters, which were then washed with
2 × 2ml cold water. The amount of GMP transported inside the liposomes was
calculated by scintillation counting in Ultima Gold (Perkin Elmer)
For IC50 calculations the liposomes contained 0.5 mM GMP on the inside and
the external buffer contained the desired amount of cold competitor. The uptake of
radiolabelled substrate was stopped at the desired time (3 min) by rapidly ﬁltering
onto 0.22-μm ﬁlters, which were then washed with 2 × 2 ml cold water. The
amount of GMP transported inside the liposomes was calculated by scintillation
counting in Ultima Gold (Perkin Elmer). For IC50 values the whole experiment was
repeated in triplicate to calculate the mean and s.d. For every experiment a control
using WT protein was conducted alongside, however the data shown in the ﬁgures
was data published previously10. A representative curve is shown for each main
ﬁgure, with the mean and s.d. shown in a bar chart. All the IC50 curves are shown
in supplementary data (Supplementary Fig. 9 and 10).
For the analysis of rates under different antiport conditions, liposomes were
loaded with 0.5 mM of the substrate (or 1 mM for AMP) on the inside and 20 μM
of either GMP or GDP-mannose, with a trace amount of 3 H substrate on the
outside. Time points were taken to produce an initial linear rate (Supplementary
Fig. 4). The amount of substrate transported at 45 s is shown in the main ﬁgure.
These experiments were performed at 22 °C.
For the mixed dimer analysis, a total of 1 μg of protein was added to 50 μl of
assay buffer containing 0.5 μM 3H-GMP, which initiated the transport. Transport
was monitored over time with time points taken at 10, 20, 30, and 60 min. The
main ﬁgure shows the relative transport at 45 s. Each experiment was repeated in
triplicate. In addition, the entire analysis was repeated using protein from separate
puriﬁcations.
Thermal stability measurements. Thermal stability of protein samples was
analysed using a Prometheus NT.48 (NanoTemper Technologies)39. The proteins
were diluted to a ﬁnal concentration of 0.7 mg ml−1 into buffer containing 20 mM
Hepes, pH 7.5, 50 mM KCl, 2 mM magnesium sulphate and 0.03% (w/v) DDM or
0.3% DM. Thermal measurements were carried out in a range from 20 to 95 °C
with 1 °C per min steps. The resulting melting curves were generated by plotting
the ﬁrst derivative of the ﬂuorescence ratio at 330 nm/350 nm (excitation 280 nm)
against temperature. For stability in the presence of ligand (GMP) the ligand was
added to the sample at a ﬁnal concentration of 0.5 mM and the sample was
incubated at room temperature for 5 min prior to analysis. For the sample in
liposomes, reconstituted Vrg4, at a protein concentration of 0.4 mg ml−1, in yeast
polar lipids were prepared in 20 mM Hepes, pH 7.5, 50 mM KCl, 2 mMmagnesium
sulphate and extruded through a 0.4 μm membrane prior to analysis. For the
solubilised liposome sample, liposomes were solubilised in 1.5% DDM for one hour
and centrifuged at 100,000 × g for 30 min prior to analysis.
Coarse grained molecular dynamics. Vrg4 dimer coordinates were converted to
the Martini 2.2 protein representation40. In addition to the bonds implicit in the
Martini force ﬁeld, elastic bonds of 1000 kJ mol−1 nm−2 were applied between
protein backbone beads within 1 nm across the full Vrg4 dimer. The protein was
then built into a lipid bilayer composed of 875 dipalymitoylphosphatidylcholine
(C16:0; DPPC) molecules and 875 dimyristoylphosphatidylcholine (C14:0; DMPC)
molecules, distributed equally between the two leaﬂets. Note that, due to the coarse
nature of the Martini force ﬁeld, the DPPC and DMPC lipids also represent C18:0
and C12:0 tails respectively. The membranes were built using the insane method41
and solvated with Martini water and Na and Cl to 150 mM. Three independent
repeats, each from an independently constructed membrane, were run out to
12–15 µs each, using 20 fs time steps, in the NPT ensemble at 323 K with the V-
rescale thermostat and semi-isotropic Parrinello–Rahman pressure coupling42. For
analysis purposes, the ﬁrst 4 µs were discarded. Densities for both the DPPC and
DMPC lipids were computed using the volpam utility in VMD43 and Gaussian
smoothed with a resolution of 0.2 nm. Densities were averaged over the three
repeats for the main ﬁgures.
For the bilayer thickness simulations, Vrg4 dimers were built into membranes
comprising just DPPC or DMPC lipids. Bilayer thicknesses were assessed over the
duration of > 3 µs CG simulations.
Atomistic simulations. A post-15 µs snapshot of the DPPC/DMPC CG data was
trimmed in size and converted to an atomistic description44, using the
CHARMM36 force ﬁeld45 modiﬁed to include virtual-sites46. Missing loops were
added using SWISS-MODEL47. The systems were solvated with TIP3P water and
Na+ and Cl− ions were added to 150 mM. The systems were energy minimised
using the steepest descents method, then equilibrated with positional restraints on
heavy atoms for 100 ps in the NPT ensemble at 310 K with the V-rescale ther-
mostat and semi-isotropic Parrinello–Rahman pressure coupling42. Production
simulations were run without positional restraints, with 4 fs time steps over 30 ns.
Lipid contact was analysed using MDAnalysis48, where residue-lipid distances
below 0.4 nm were considered as contacts.
All simulations were run using GROMACS 201849.
Data availability
Data supporting the ﬁndings of this manuscript are available from the corresponding
authors upon reasonable request. A reporting summary for this Article is available as
a Supplementary Information ﬁle. Atomic coordinates for the crystal structure have been
deposited in the Protein Data Bank under accession number 6QSK. The source data
underlying Figs. 2a-d, 3, 4e and Supplementary Figs 4, 5, 9 and 10 are provided as a
Source Data ﬁle.
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